class action lawsuit

Class action lawsuit filed against Sallie Mae for allegedly concealing loan delinquency increases and overstating loss mitigation effectiveness, artificially inflating stock prices during July-August 2025.

Varonis Systems faces class action lawsuit alleging false statements about SaaS conversion capabilities artificially inflated stock prices, harming shareholders during February-October 2025.

Ramaco Resources faces class action lawsuit for allegedly misrepresenting Brook Mine's operational status, failing to disclose lack of mining activity despite groundbreaking ceremony claims.

Class action lawsuit filed against Smart Digital Group for allegedly failing to disclose market manipulation and fraudulent promotional activities that harmed investors between May and September 2025.

Schall Law Firm files securities fraud class action against Picard Medical for allegedly misleading investors through false statements and an alleged "pump and dump" scheme during September-October 2025.

BellRing Brands faces securities lawsuit over false statements. Lead plaintiff deadline is March 23, 2026 for eligible investors who suffered losses.

REGENXBIO faces class action lawsuit alleging securities violations over failure to disclose adverse information about RGX-111 before FDA clinical hold.

Schall Law Firm sues Ardent Health for securities fraud, alleging material misrepresentations about accounts receivable practices and insurance coverage between July 2024 and November 2025.

Ardent Health faces securities class action for allegedly inflating receivables through misleading accounting practices. Class period runs July 2024 through November 2025.

Schall Law Firm files class action against Charming Medical over SEC trading suspension, alleging securities fraud from coordinated social media promotion scheme driving suspicious stock spike.

KDDI faces securities investigation over delayed earnings disclosure and potential misleading business information. Stock fell 11.4% as Rosen Law Firm explores class action litigation for shareholders.

Kyndryl investors face April 13 deadline to become lead plaintiff in securities class action over financial reporting failures and misstatements.

Securities lawsuit against uniQure alleges misleading FDA disclosure statements about gene therapy candidate AMT-130. Stock fell 49% after November FDA feedback; investors must file claims by April 13, 2026.

REGENXBIO faces securities fraud lawsuit for allegedly making false statements about RGX-111 safety while withholding adverse trial data from investors between February 2022 and January 2026.

Nidec's stock plunges 22.7% after announcing accounting irregularities at its China unit. Class action litigation launched investigating potential securities law violations and shareholder damages.

UniQure faces class action lawsuit over alleged FDA disclosure misrepresentations. Investors have until April 13, 2026 deadline to join litigation.

Law firm investigates CoreWeave for allegedly concealing data center construction delays. Stock fell $14B after December disclosure of months-behind Texas facility project.

BellRing Brands faces securities fraud investigation for allegedly misrepresenting 2025 sales growth, attributing gains to retail inventory buildup rather than organic demand. Stock fell 33%.

Law firm sues uniQure for allegedly misrepresenting gene therapy trial status and FDA approval timeline, causing stock to surge 250% then fall 49% after FDA reversal.

REGENXBIO faces securities lawsuit for allegedly misleading investors about RGX-111 gene therapy safety concerns. FDA imposed clinical hold after trial participant developed CNS tumor.